LIMN
Liminatus Pharma, Inc.Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
- R May 22 Liminatus Pharma received a Nasdaq delisting notice after failing to…
- X Jul 31 Short interest jumps 76.1% to 4.23M
- X Aug 14 Short interest jumps 144.0% to 10.33M
- R Aug 18 Liminatus Pharma filed an 8-K confirming a 1-for-50 reverse stock sp…
- E Aug 20 Trading halt: Trading Halt: LIMN — T1 (News Pending)
- E Aug 24 FDA: Liminatus Pharma Engages Synex as Contract Research Organi…
- X Aug 31 Short interest falls 99.1% to 95.5K
- X Sep 15 Short interest falls 38.4% to 58.8K
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.
- InstitutionsBEARISH
Q2 2026: 0 added (0 new), 4 trimmed or exited.
- TrendDOWNTREND
19% below its 50-day average. New closing low $2.94 on Oct 23.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| CITADEL ADVISORS LLC | NEAR_EXIT | $6.2K |
| UBS Group AG | TRIM | $1.8K |
| Vanguard Personalized Indexing Management, LLC | TRIM | $1.5K |
| BlackRock, Inc. | NEAR_EXIT | $35.00 |
| GEODE CAPITAL MANAGEMENT, LLC | ADD | $20.2K |
| UBS Group AG | DOUBLED | $9.4K |
| CITIGROUP INC | DOUBLED | $1.2K |
| Farther Finance Advisors, LLC | TRIM | $2.00 |
Quarterly 13F filings are due 45 days after each quarter ends.
Insider ledger
Form 4| Date | Insider | Type | Value |
|---|---|---|---|
| Jul 2, 2026 | Valetudo Therapeutics LLC Chief Executive Officer | OTHER | 3,448,926 sh |
| Jun 24, 2026 | Valetudo Therapeutics LLC Chief Executive Officer | OTHER | 4,373,603 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | — | — | — | $0.00 |
| Next Q | — | — | — | $0.00 |
| Current FY | — | — | — | $0.00 |
| Next FY | — | — | — | $0.00 |
Short side
FINRA· Oct 15, 2026| Aug 20, 2026 | Resumption Scheduled | Resumed |
SecBot reports
3 filings · 2 press releases · 0 bullish · 2 bearish · 1 neutral- BEARISH 8-KAug 18, 2026
Liminatus Pharma filed an 8-K confirming a 1-for-50 reverse stock split to regain compliance with…
The reverse split is a purely mechanical fix to avoid delisting and does not improve the company's financial health or pipeline prospects. Monitor the stock price closely on Aug 21 (first…
- BEARISH 8-KJul 6, 2026
Liminatus Pharma completed its acquisition of InnocsAI LLC via merger on July 2, 2026. The total…
Massive dilution is locked in — the immediate issuance of ~11.2M common shares at $0.20 is already pricing in further weakness, but the real overhang is the ~1.59 billion share equivalent in…
- NEUTRAL S-1Jun 23, 2026
Liminatus Pharma filed an S-1 registration statement for the resale of up to 20,688,000 shares of…
This S-1 is a routine resale registration for an existing holder; no primary capital raise. Monitor the pending InnocsAI merger (1.6B shares at $0.20) and Nasdaq compliance status. The company's…
- BEARISH PRESS RELEASEMay 21, 2026
Liminatus Pharma received a Nasdaq delisting notice after failing to regain compliance with the…
The appeal stay provides a temporary reprieve, but the fundamental gap between $8M market cap and $50M MVLS requirement makes compliance nearly impossible. Expect eventual delisting and OTC trading…
All LIMN filing & press-release reports (5)
- 8-K reportAug 18, 2026
- 8-K reportJul 6, 2026
- S-1 reportJun 23, 2026
- PRESS-RELEASE reportMay 21, 2026
- PRESS-RELEASE reportMar 17, 2026